Addex Therapeutics
ADXN
4 hedge funds and large institutions have $20.4M invested in Addex Therapeutics in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
592% more capital invested
Capital invested by funds: $2.94M → $20.4M (+$17.4M)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
4.02% more ownership
Funds ownership: 4.92% → 8.94% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.83M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$508K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$121K |
ADXN Hedge Fund Activity: Q2 2021 in Review
4 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q2 2021, worth a combined $20.4M — up 592% from $2.94M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ADXN positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $1.83M. The largest seller was Citadel Advisors, exiting entirely with an estimated $121K sold.
- 4 institutional investors held Addex Therapeutics (ADXN) as of Q2 2021, up from 3 in Q1 2021.
- Funds reported $20.4M of Addex Therapeutics stock for Q2 2021, up 592% quarter-over-quarter.
- 2 funds opened new Addex Therapeutics positions in Q2 2021 and 1 closed out, a net change of +1 holder.
- The largest Addex Therapeutics buyer in Q2 2021 was NEA Management Company, an estimated $1.83M added.
- The largest Addex Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $121K sold.
Based on aggregated 13F filings for Q2 2021.